Get the Stockscreener App
0.74
3.90%
-0.03
Gri Bio Inc stock is traded at $0.74, with a volume of 211.70K.
It is down -3.90% in the last 24 hours and up +15.81% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$0.77
Open:
$0.7705
24h Volume:
211.70K
Relative Volume:
0.05
Market Cap:
$6.61M
Revenue:
-
Net Income/Loss:
$-13.28M
P/E Ratio:
-0.1612
EPS:
-4.5911
Net Cash Flow:
$-8.99M
1W Performance:
-7.50%
1M Performance:
+15.81%
6M Performance:
-70.52%
1Y Performance:
-97.99%
1-Day Range:
$0.74
$0.79
1-Week Range:
$0.7348
$0.8449
52-Week Range:
$0.3015
$65.00
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
0.74 | 6.61M | 0 | -13.28M | -8.99M | -30.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
GRI Bio (NASDAQ:GRI) Now Covered by HC Wainwright - Defense World
GRI Bio Inc (NASDAQ: GRI): What’s Next After The Stock Plunge? - Stocks Register
Astera Labs Inc: Is ALAB Stock Worth Buying? - Stocks Register
HC Wainwright & Co. Initiates Coverage of GRI Bio (GRI) with Buy Recommendation - MSN
GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
GRI Bio to Present Corporate Strategy at Virtual Investor Closing Bell Series - StockTitan
GRI Bio reports progress in IPF treatment with GRI-0621 - Investing.com India
GRI Bio Showcases GRI-0621’s Potential to Reduce - GlobeNewswire
GRI Bio's IPF Drug Shows Promise in Preclinical Data, Phase 2a Trial Underway | GRI Stock News - StockTitan
GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) - The Manila Times
GRI Bio files to sell 1.58M shares of common stock for holders - MSN
SEC Form 424B3 filed by GRI Bio Inc. - Quantisnow
GRI Bio Inc (GRI) Quarterly 10-Q Report - Quartzy
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis - GlobeNewswire
GRI Bio Raises $13.9M, Extends Runway for Key IPF Drug Trial Data in 2025 | GRI Stock News - StockTitan
GRI Bio Inc expected to post a loss of 73 cents a shareEarnings Preview - XM
Ascendiant Capital Initiates Coverage of GRI Bio (GRI) with Buy Recommendation - MSN
Curis (CRIS) Stock Plummets Over 5% Amid Lack of Institutional R - GuruFocus.com
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
Primary Sclerosing Cholangitis Pipeline 2024: Clinical Trials - openPR
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.80% - MSN
GRI Bio secures funding to advance IPF treatment into 2025 - Investing.com India
GRI Bio secures funding to advance IPF treatment into 2025 By Investing.com - Investing.com UK
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024 - GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Dow Falls Over 150 Points; General Motors Tops Q3 Views - Benzinga
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.80% - MSN
GRI Bio Announces Exercise of Warrants - GlobeNewswire
Dyne Therapeutics (DYN) Shares Plummet Amid Market Volatility - GuruFocus.com
Top Innovation Stocks Surge: PRSO, SYTA, SAVE, ISPC, GRI, BIVIMust-Watch Stocks This Week - openPR
Energy storage ‘key’ to sustainability – report - Yahoo! Voices
As iPhone Sales Soar in China, Is It Time to Buy Apple Stock? - Yahoo! Voices
2 Artificial Intelligence (AI) Stocks That Are No-Brainer Buys - Yahoo! Voices
Statkraft seeks approval for 2.1GW offshore wind farm in Baltic Sea - Yahoo! Voices
BioPorto A/S Announces Changes to the US Commercial Organization - Yahoo Finance
CRISPR-based Gene Editing Market Report 2024-2030, Featuring Revvity, Danaher, GenScript, Merck, Tocris Bioscience, OriGene Technologies, Bio-Rad Laboratories, Bio-Techne & New England Biolabs - Yahoo Finance
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement - Yahoo Finance
Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis - Yahoo! Voices
Amcor reports 9% drop in greenhouse gas emissions in 2024 - Yahoo! Voices
Esso Australia completes Kipper Compression Project - Yahoo! Voices
Final countdown: 7 days until TechCrunch Disrupt 2024 kicks off - Yahoo! Voices
Cigna and Humana re-engage in merger talks - Yahoo! Voices
Starr Insurance to operate in Seoul, South Korea - Yahoo! Voices
Alliance Group gets insurance intermediary licence in Germany - Yahoo! Voices
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
Live Oak Ventures Participates in Financing of Synply, Inc. - Yahoo Finance
US Stocks Edge Lower; Dow Falls 50 Points - Benzinga
T-Mobile partnership has this beaten down stock launching 🚀 - RagingBull
2 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire - Yahoo! Voices
Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year? - Yahoo Finance
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):